Neuropeptide Y enhances permeability across a rat aortic endothelial cell monolayer
Authors:
- Guo-Gang FengGFGuo-Gang Feng
- Yoshihiro HottaYHYoshihiro Hotta
- Kimitoshi NishiwakiKNKimitoshi Nishiwaki
- Yasuhiro ShimadaYSYasuhiro Shimada
- Atsuko IshikawaAIAtsuko Ishikawa
- Nakako KurimotoNKNakako Kurimoto
- Tatsuro ShigeiTSTatsuro Shigei
- Naohisa IshikawaNINaohisa Ishikawa
- 1 March 2004
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 286 (3) , H1027-H1033
Abstract
Previously, in vivo studies showed that neuropeptide Y (NPY) elevates vascular permeability in isolated lung perfusion preparations, possibly through binding to the NPY Y3receptor. The present study used monolayers in a double-chamber culture method under conditions of normoxia (5% CO2-20% O2-75% N2) or hypoxia (5% CO2-5% O2-90% N2) to test the hypothesis that NPY directly affects rat aortic endothelial cells (RAECs). RAECs were cultured on the base of the upper chamber, into which FITC-labeled albumin was introduced, and permeation into the lower chamber was measured. The RAEC monolayer was treated with 10–8–3 × 10–7M NPY for 2 h in normoxia or hypoxia. In hypoxia, NPY concentration dependently increased the permeability of the RAEC monolayer, whereas in normoxia no significant change was observed. Peptide YY, NPY Y1, and NPY Y2receptor agonists and NPY Y1receptor antagonist exerted no significant effects under hypoxic conditions. NPY-(18–36), an NPY Y3receptor antagonist, elicited an inhibitory action on the NPY-induced increase in monolayer permeability. Furthermore, neither N-monomethyl-l-arginine, a nitric oxide synthase inhibitor, the bradykinin B2receptor antagonist FK-3657, nor the vascular endothelial growth factor receptor-coupled tyrosine kinase inhibitor tyrphostin SU-1498, injected into the medium of the upper chamber, affected the NPY-induced permeability changes under hypoxic conditions. The results suggest that the NPY-induced increase in permeability across the RAEC monolayer is closely related to low O2tension, possibly mediated by direct action on the NPY Y3receptor expressed on the endothelial cell membrane. Furthermore, this NPY-induced increase is not likely due to nitric oxide, bradykinin, or vascular endothelial growth factor.Keywords
This publication has 40 references indexed in Scilit:
- Neuropeptide Y in the Sheep Fetus: Effects of Acute Hypoxemia and Dexamethasone During Late GestationEndocrinology, 2000
- Effect of Axotomy on Expression of NPY, Galanin, and NPY Y1 and Y2 Receptors in Dorsal Root Ganglia and the Superior Cervical Ganglion Studied with Double-Labeling in Situ Hybridization and ImmunohistochemistryExperimental Neurology, 2000
- Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca 2+ signallingPflügers Archiv - European Journal of Physiology, 1999
- Hypoxia Induces Vascular Endothelial Growth Factor in Cultured Human Endothelial CellsJournal of Biological Chemistry, 1995
- Neuropeptide Y effector systems: perspectives for drug developmentTrends in Pharmacological Sciences, 1994
- Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YYLife Sciences, 1992
- Release of immunoreactive-neuropeptide Y by rat plateletsBiochemical and Biophysical Research Communications, 1988
- Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous systemLife Sciences, 1986
- Co-release of neuropeptide Y and catecholamines during physical exercise in manBiochemical and Biophysical Research Communications, 1985
- Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels.Journal of Clinical Investigation, 1983